RxDoctor Payments Data

Charles Hare, MD

Internal Medicine · San Francisco, CANPI 1538276324

Payments from drug & device makers

$1,273,554in general payments, 2019–2025

Across 106 payments — averaging $12,015 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$918K
  • Sanofi Pasteur Inc.$265K
  • Viiv Healthcare Company$49K
  • Merck$42K
  • Intuitive Surgical$149

What the payments were for

  • Food & beverage$149100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead64$917,636
Sanofi Pasteur Inc.4$264,615
Viiv Healthcare Company17$49,398
Merck20$41,756
Intuitive Surgical1$149

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,273,554 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$5,572
Medicare patients
12
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala80$852,540
OdefseyEmtricitab/Rilpiviri/Tenof Ala53$419,530
PrezcobixDarunavir/Cobicistat53$348,712
TivicayDolutegravir Sodium41$328,803
TriumeqAbacavir/Dolutegravir/Lamivudi35$306,313
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$252,824
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf18$252,143
JulucaDolutegravir/Rilpivirine18$190,907
SerostimSomatropin12$159,077
DescovyEmtricitabine/Tenofov Alafenam25$157,202
IsentressRaltegravir Potassium26$94,523
PifeltroDoravirine16$92,392
Maraviroc16$36,257
Etravirine23$23,470
Typhim ViTyphoid Vi Polysacch Vaccine238$20,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$917,636$1,262,565129 claims
Viiv Healthcare CompanyTivicay, Triumeq, Juluca$49,398$826,02394 claims
MerckIsentress, Pifeltro$41,756$186,91542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →